Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

16.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
16.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

ESMO open·2026
Same author

Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).

ESMO open·2026
Same author

Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer.

Cell death & disease·2026
Same author

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology.

Cancer treatment reviews·2026

Related Experiment Video

Updated: Feb 28, 2026

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.7K

CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies.

J Remon1, N Abedallaa1, E Taranchon-Clermont2

  • 1Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805 Villejuif, France.

Lung Cancer (Amsterdam, Netherlands)
|June 20, 2017
PubMed
Summary
This summary is machine-generated.

New research identifies potential predictive markers for thymic epithelial tumors (TETs). Biomarker expression, including Insulin-like Growth Factor 1 Receptor (IGF-1R), varies by TET subtype, guiding future clinical trials and targeted therapies.

Keywords:
CD22CD26CD52EG5IGF-1RThymic

More Related Videos

Examination of Thymic Positive and Negative Selection by Flow Cytometry
14:29

Examination of Thymic Positive and Negative Selection by Flow Cytometry

Published on: October 8, 2012

22.7K
Co-Culture and Transduction of Murine Thymocytes on Delta-Like 4-Expressing Stromal Cells to Study Oncogenes in T-Cell Leukemia
09:43

Co-Culture and Transduction of Murine Thymocytes on Delta-Like 4-Expressing Stromal Cells to Study Oncogenes in T-Cell Leukemia

Published on: June 9, 2023

2.6K

Related Experiment Videos

Last Updated: Feb 28, 2026

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.7K
Examination of Thymic Positive and Negative Selection by Flow Cytometry
14:29

Examination of Thymic Positive and Negative Selection by Flow Cytometry

Published on: October 8, 2012

22.7K
Co-Culture and Transduction of Murine Thymocytes on Delta-Like 4-Expressing Stromal Cells to Study Oncogenes in T-Cell Leukemia
09:43

Co-Culture and Transduction of Murine Thymocytes on Delta-Like 4-Expressing Stromal Cells to Study Oncogenes in T-Cell Leukemia

Published on: June 9, 2023

2.6K

Area of Science:

  • Oncology
  • Cancer Biomarkers
  • Translational Research

Background:

  • Thymic epithelial tumors (TETs) are rare malignancies requiring novel therapeutic strategies.
  • Identifying predictive biomarkers is crucial for advancing clinical trial development in TETs.
  • This study investigates five specific biomarkers with potential therapeutic targets.

Purpose of the Study:

  • To evaluate the expression of five potential predictive biomarkers in thymic epithelial tumors.
  • To correlate biomarker expression with histological subtypes of TETs.
  • To identify actionable targets for new treatment options in TET patients.

Main Methods:

  • Immunohistochemistry was used to assess the expression of CD52, CD22, CD26, EG5, and IGF-1R.
  • Formalin-fixed surgical samples from 106 TET patients were analyzed.
  • A threshold of 10% positive epithelial tumor cells determined marker positivity.

Main Results:

  • CD52, CD22, CD26, EG5, and IGF-1R were expressed in 7%, 42%, 25%, 42%, and 77% of samples, respectively.
  • EG5 expression was significantly higher in thymic carcinomas compared to thymomas (75% vs. 38%, p=0.026).
  • Specific markers showed differential expression across thymoma subtypes and thymic carcinoma.

Conclusions:

  • The expression patterns of CD52, CD22, CD26, EG5, and IGF-1R provide insights into TET biology.
  • Targeted therapies acting on CD52, CD22, CD26, and EG5 warrant further investigation in TET patients.
  • Findings support the exploration of these biomarkers for personalized treatment strategies in thymic cancers.